{
    "2020-10-15": [
        [
            {
                "time": "",
                "original_text": "【天风医药】贝达药业：前三季度净利润高增长，埃克替尼销量稳步增长",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利润",
                        "高增长",
                        "埃克替尼",
                        "销量"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558.SZ)：控股股东凯铭投资质押396万股",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "控股股东",
                        "凯铭投资",
                        "质押"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "一图解码：加科思药业赴港IPO王印祥继贝达药业后的二次创业",
                "features": {
                    "keywords": [
                        "加科思药业",
                        "IPO",
                        "王印祥",
                        "贝达药业",
                        "二次创业"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "人民金融·创新药指数涨0.9% | 智飞生物、贝达药业等公司的8个重磅药品有望在年底左右获批，18个报产创新药纳入优先审评",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "智飞生物",
                        "贝达药业",
                        "重磅药品",
                        "优先审评"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：归母业绩高增长 埃克替尼保持良好增长态势",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "归母业绩",
                        "高增长",
                        "埃克替尼",
                        "增长态势"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业(300558)：业绩表现亮眼 Q3埃克替尼销售出色 2020全年可期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "业绩表现",
                        "Q3",
                        "埃克替尼",
                        "销售",
                        "2020全年"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}